Prostate Cell News Volume 4.32 | Aug 23 2013

P2Y2 Receptor Promotes Cell Invasion and Metastasis in Prostate Cancer Cells
Researchers aimed to determine whether P2Y2, one subtype of P2Y receptors, is involved in the invasion and metastasis of prostate cancer cells, and elucidate the underlying mechanism. [Br J Cancer] Abstract

Effects of Platelet-Activating Factor and Its Differential Regulation by Androgens and Steroid Hormones in Prostate Cancers
Platelet-activating factor is an arachidonic acid metabolite that plays an important role in cell proliferation, migration and neoangiogenesis, but whether it is involved in the progression of prostate cancer remains undiscovered. Clinical prostate specimens were investigated using the immunohistochemistry method and in vitro cell experiments were examined using the MTS cell proliferation assay, invasion and migration experiments, quantitative real-time RT-PCR assay, western blotting analysis and the ELISA assay. [Br J Cancer] Abstract

Hyperglycemia-Induced Chemo-Resistance of Prostate Cancer Cells Due to Insulin-Like Growth Factor Binding Protein-2
Insulin-like growth factors and their binding proteins are important mediators of the effects of nutrition on growth and play a key role in the development of prostate cancer. Researchers used DU145, PC3 and LNCaP prostate cancer cell lines to examine how hyperglycemia altered their response to docetaxel. [Endocr Relat Cancer] Abstract

Activation of Polyamine Catabolic Enzymes Involved in Diverse Responses against Epibrassinolide-Induced Apoptosis in LNCaP and DU145 Prostate Cancer Cell Lines
The authors investigated the mechanism of apoptotic cell death induced by epibrassinolide (EBR), related with polyamine biosynthetic and catabolic pathways in LNCaP (androgen receptor (AR)+), DU145 (AR−) prostate cancer cell lines and PNT1a normal prostate epithelial cell line. Induction of apoptotic cell death was observed in prostate cancer cell lines after EBR treatment. [Amino Acids] Abstract

Dual Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
Researchers explored the efficacy of NVP-BEZ235, a dual PI3K and mTORC1/2 inhibitor, for docetaxel resistant castration resistant prostate cancer. They investigated the efficacy of NVP-BEZ235 monotherapy and NVP-BEZ235 combined with docetaxel in vitro and in vivo. [J Urol] Abstract

Triterpene Saponosides from Lysimachia Ciliata Differentially Attenuate Invasive Potential of Prostate Cancer Cells
Researchers analyzed the specificity, selectivity and versatility of desglucoanagalloside B effects on human prostate cancer cells derived from prostate cancer metastases to brain and bone. Prominent growth arrest and apoptotic response of both cell types was observed in the presence of sub-micromolar desglucoanagalloside B concentrations. [Chem Biol Interact] Abstract

CLINICAL RESEARCH

Gleason Grade Progression Is Uncommon
Researchers identified a significant interaction between stage and diagnosis date predicting grade, and suggest that the relationship between grade and stage varies by time period. As the dramatic shift in stage since the introduction of prostate-specific antigen screening was accompanied by a more modest shift in Gleason grade, these findings suggest that grade may be established early in tumor pathogenesis. [Cancer Res] Abstract | Press Release

Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1
The diagnostic and prognostic properties of miR-96 expression levels were investigated by qRT-PCR in two well documented prostate cancer cohorts. The miR-96 expression was found to be significantly higher in prostate cancer patients and correlate with WHO grade, and decreased overall survival time; patients with low levels of miR-96 lived 1.5 years longer than patients with high miR-96 levels. [PLoS One] Full Article

Pharmacodynamic Study of Disulfiram in Men with Non-Metastatic Recurrent Prostate Cancer
Although many mechanisms for disulfiram’s anticancer activity have been proposed, tumor suppressor gene re-expression through promoter demethylation emerged as one of the more plausible. Scientists conducted an open-label, dose escalation trial of disulfiram in men with non-metastatic recurrent prostate cancer after local therapy. [Prostate Cancer Prostatic Dis] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.

Mayo Clinic Center for Individualized Medicine Helps Treat Complex Cancers, Solve Medical Mysteries
To help Mayo Clinic physicians and researchers usher in a new age of medicine that uses technologies like whole genome sequencing to find solutions for patients, Cecilia and Dan Carmichael have donated $5 million to Mayo. [Mayo Foundation for Medical Education and Research] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Prostate Cancer Research (Mount Sinai School of Medicine)

Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Postdoctoral Position – Prostate Cancer (Tulane University)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Fellow – Steroid Receptor Signaling (Baylor College of Medicine)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Lead Research Technologist – Translational Prostate Cancer Research Program (Cleveland Clinic)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.